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ABSTRACT
Retinoic acid (RA)-dependent activation of the RA receptor b2
(RARb2) gene in embryonal carcinoma cells is mediated by binding of
retinoid receptor heterodimers (RAR/RXR) to a RA response element
(RARE) located closely to the TATA box. We have analyzed the effect
of vitamin D on the response of the RARb2 promoter to RA in pituitary
GH4C1 cells that coexpress receptors for retinoids and vitamin D.
Incubation with vitamin D markedly reduced the response to RA
caused by transcriptional interference of the vitamin D receptor
(VDR) on the RARE. This DNA element binds VDR/RXR het-
erodimers with high affinity, and these inactive heterodimers can
displace active RAR/RXR from the RARE. Overexpression of RXR in
GH4C1 cells, as well as incubation with BMS649 (a RXR-specific
ligand), increased the inhibitory effect of vitamin D, suggesting that
the VDR/RXR heterodimer is the repressive species and that titration
of RXR is not responsible for this inhibition. Although DNA binding
could be required for full potency of the inhibitory activity of VDR, it
is not absolutely required because a truncated receptor (VDR D1–
111), lacking the DNA binding domain, also displays repressor ac-
tivity. Furthermore, the ability to mediate transrepression by vitamin
D was strongly decreased when a mutant VDR in which the last 12
C-terminal aminoacids have been deleted (VDR DAF-2) was used.
Because this region contains the domain responsible for ligand-
dependent recruitment of coactivators, titration of common coactiva-
tors for VDR and RAR could be involved in the inhibitory effect of
vitamin D. In agreement with this hypothesis, overexpression of E1A,
which can act as a RARb2 promoter-specific coactivator, significantly
reversed repression by vitamin D. (Endocrinology 140: 2898–2907,
1999)
THE NUCLEAR RECEPTORS for vitamin D (VDR) andretinoic acid (RAR) are ligand-inducible transcription
factors that exert their actions by binding, preferentially as
heterodimers with the retinoid receptor RXR, to hormone
response elements (HREs) located in regulatory regions of
target genes. These receptors are members of a larger group
of factors that also include the thyroid and steroid hormone
receptors, as well as orphan receptors (1–2). The nuclear
receptors exhibit a modular structure consisting of regions A
through E or F. The A/B region contains an autonomous
ligand-independent transactivating function (AF-1). This is
an atypical region in VDR because it contains only 20 ami-
noacids, and deletion of these residues does not seem to alter
receptor function (3). Region C, the most conserved through-
out the superfamily, contains the two zinc finger structures
responsible for DNA binding; the flexible hinge D region
connects the DNA binding domain (DBD) with region E,
which contains the ligand binding domain (LBD), the dimer-
ization domain, and a C-terminal ligand-dependent trans-
activation function (AF-2) (4–6).
Naturally occurring and synthetic HREs are normally
composed of at least two copies of the consensus AGGTCA
motif arranged as direct repeats (DRs), palindromes, or in-
verted repeats. The heterodimers bind with a specific polar-
ity in the DRs (7, 8). Studies on the spacing of half-sites,
arranged as DRs, have demonstrated that VDR preferentially
mediates ligand-dependent transactivation via a DR sepa-
rated by three nucleotides (DR3), whereas RAR transacti-
vates via DRs with a two- or five-nucleotide gap (9). Al-
though the orientation and spacing of the half-sites can
determine selective transcriptional responses, specificity is
not total, and some HREs can bind different heterodimers
with high affinity. It has been shown that VDR/RXR can bind
not only to DR3 but also to DR4, DR5, and palindromic
elements (10, 11). In some cases, retinoic acid (RA) and vi-
tamin D can cooperate to stimulate transcription through the
same element. However, only a subset of receptor DNA
binding elements function as response elements. Thus,
VDR/RXR can bind to RA response elements (RAREs) in a
transcriptionally inactive form; and under these circum-
stances, vitamin D can inhibit the response to RA (10).
This suggests that transcriptional responses to RA could
be selectively repressed in cells containing receptors for
vitamin D.
The RARb2 promoter has been extensively used as a
model for transcriptional regulation by RA. This promoter
contains a strong and well-characterized DR5-type RARE
(bRARE) located at nucleotides 237 to 253, with respect to
transcription initiation (12–14). More recent studies have
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shown the presence of a weaker RARE at positions 267 to
283 (15). The close proximity of the RAREs to the TATA box,
rather than the arrangement of these elements, seems to be
crucial to establish productive interactions of the receptor
heterodimers with neighboring components of the basal
transcriptional machinery (15). It has been shown that li-
gand-dependent transcriptional activation by nuclear recep-
tors depends on the presence of an autonomous AF-2 in the
LBD. Recent studies have solved the crystal structure of the
LBDs of the apo RXR and holo RAR (16, 17). These studies
have proven that RA binding induces a structural modifi-
cation in helix 12 of the LBD that contains the AF-2. This
change allows the recruitment of coactivator proteins and a
ligand-dependent transcriptional activation. Different fam-
ilies of coactivators (including SRC-1/NCoA-1, TIF2/
GRIP1/NCoA-2, pCIP/ACTR/AIB1/RAC3/TRAM1, and
CBP/p300, a cointegrator of multiple signal transduction
pathways) have been recently cloned (18, 19). Although these
proteins can each serve as coactivators of several nuclear
receptors, cell-type-specific or receptor-specific proteins may
also play important roles in controlling transcriptional re-
sponses to different nuclear receptor ligands. The RARb2
promoter is strongly activated by RA in undifferentiated
embryonal carcinoma (EC) cells, and the TATA binding pro-
tein (TBP) functionally cooperates with RAR in the transac-
tivation of this promoter. This cooperation seems to require
the presence of a cell-specific E1A-like activity (E1A-LA),
which is lost during differentiation (20, 21). Ectopic expres-
sion of the adenovirus E1A(13S) protein in differentiated
cells is a prerequisite for TBP and RAR cooperation (20). It
has been shown that E1A directly interacts with the AF-2
domain of RAR (22). Because E1A also associates with TBP
(23), it has been proposed that E1A functions as a coactivator
or bridging protein by interacting with both TBP and RAR,
thereby stabilizing the preinitiation complex (22).
In this study, we have analyzed the influence of vitamin
D on the activation of the RARb2 promoter by RA in pituitary
GH4C1 cells that coexpress RAR and VDR. Our results show
that vitamin D exerts a strong dominant negative activity on
RA-mediated transcriptional stimulation of this promoter.
VDR/RXR heterodimers bind to the bRARE and can displace
RAR/RXR binding in in vitro gel retardation assays. Al-
though competition for DNA binding by transcriptionally
inactive VDR/RXR heterodimers may contribute to this in-
hibitory response, our data also show that a mutant VDR,
lacking the A/B domain and the DBD, also displays a dom-
inant negative activity. Furthermore, an AF-2 defective C-
terminally truncated VDR was unable to mediate transre-
pression, suggesting that titration of coactivators is involved
in the inhibitory effect of vitamin D. In agreement with this
hypothesis, overexpression of E1A significantly reverses the
inhibition caused by vitamin D.
Materials and Methods
Plasmids
R-140 CAT construct, containing the fragment 2124 to 114 of the
human RARb2 promoter, was obtained from the previously described
R-140 Luc (14). The promoter fragment was obtained by PCR with the
oligonucleotides 59-GGGAAGCTTGGATCCTGGGAGTTGGT-39 and
59-GCTCTAGAGCTCACTTCCTACTAC-39 and subcloned in HindIII
and XbaI sites of pBLCAT81, replacing the thymidine kinase (tk) pro-
moter. The same strategy was used to obtain R-140 (M3) and R-140 (M7)
from the parental constructs (14). In these plasmids, the 39 (M3) and 59
(M7) half-sites of the proximal RARE have been mutated. In the con-
struct R-90 CAT, the sequences from 259 to 114 of the RARb2 promoter
were similarly cloned into the HindIII/XbaI sites of pBLCAT81. In the
plasmid Spp-1-tk-CAT, the oligonucleotide 59-AGCTTGACCAA-
CAAGGTTCACGAGGTTCACGTCTCT-39, conforming the VDRE of
the osteopontin promoter, was cloned into the HindIII and XbaI sites of
pBLCAT81 in front of the tk promoter. Expression vectors for RAR,
RXR, and VDR contain the complementary DNA sequences of the a form
of the human RAR (pRS-hRARa) (24), the human RXR a (25), and the
human VDR (26). The expression vector for the DAF2 VDR mutant was
constructed by PCR using the VDR expression plasmid as a template and
the oligonucleotides 59-GGAATTCCATGGAGGAGGAGGCCTTTG-39
and 59-CGGGATCCTCAGGAGATCTCATTGCC-39 to generate a
872-bp fragment. This fragment was digested with BstXI and BamHI and
cloned into the pSG5 expression vector. This receptor lacks the last 12
C-terminal aminoacids, which contain the AF-2 region. For the D1–111
VDR mutant, the oligonucleotides 59-GGAATTCCATGGAGGAGGAG-
GCCTTG-39 and 59-CGGGATCCTCAGGAGATCTCATTGCC-39 were
used to generate a 972-bp fragment, which was digested with EcoRI and
BamHI and subcloned into pSG5. This construct generates a truncated
receptor lacking 111 N-terminal aminoacids which include the A/B
region and the DBD (C region). The expression vectors for CBP, SRC-1,
TFIIB, TBP, and E1A(13S) have been previously described (20, 27, 28)
Cell culture, transient transfections, and CAT assays
GH4C1 cells, cultured in DMEM containing 10% FCS, were trans-
fected by electroporation, as previously described (10). Twenty-five
micrograms of the reporter plasmids were mixed with 20–30 million
cells and exposed to a high-voltage pulse (200–250 V, 960 mF). When
indicated, the reporter plasmid was cotransfected with the same amount
of expression vectors for the receptors VDR, RAR, or RXR. The cells from
each electroporation were split into different culture plates in DMEM.
COS-7 cells were cultured in DMEM containing 10% FCS and were
plated 24 h before transfection into 60-mm dishes. The cells were then
transfected with calcium phosphate with 5 mg of the reporter plasmid
(plus 100 ng of a luciferase internal control plasmid). 2.5 mg of VDRs
were used in cotransfection assays. In all cases, the total amount of DNA
from each transfection was kept equal by addition of the corresponding
empty expression vectors (RSV-0 and pSG5–0). Treatments with vitamin
D and retinoids were administered in serum-free medium. After 48 h of
treatment, CAT activity was determined by incubation of the cell extracts
with [14C]chloramphenicol. The unreacted and acetylated [14C]chlor-
amphenicol were separated by TLC and quantified with an Instantim-
ager. Each treatment with the ligands was performed at least in duplicate
cultures that normally exhibited less than 10% variation in CAT activity,
and the experiments were repeated at least two or three times with
similar relative differences in regulated expression. The results are nor-
mally expressed as the mean 6 sd of the CAT values obtained.
Western blot analysis
Extracts from COS-7 cells, transfected with wild-type or mutant VDRs
or with the noncoding vector pSG5–0, were run in 10% or 12% poly-
acrylamide gels. The proteins were transferred to a nitrocellulose mem-
brane and incubated with either a 1:3000 dilution of the polyclonal
antibody (sc-1008x; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) that
recognizes the C-terminal region of VDR, or the same dilution of a poly-
clonal antibody (MAB1360, Chemicon International, Inc., Temecula, CA)
raised against the DBD. The proteins were identified by chemo-
luminescence.
Gel retardation assays
The vectors for VDR, RAR, and RXR (cloned in pSG5) were used for
in vitro transcription and translation with TNT Quick (Promega Corp.,
Madison, WI). The efficiency of expression, assessed in parallel reactions
using 35S[methionine], was similar for all of them. As a probe, we used
the oligonucleotide 59-GGGTAGGGTTCACCGAAAGTTCACTCG-39
corresponding to the proximal RARE of the RARb2 promoter. For the
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binding reaction, the proteins were incubated on ice for 15 min in a buffer
(10 mm HEPES-(KOH) (pH 7.9), 80 mm KCl, 1 mm dithiothreitol, 5%
Ficoll) containing 3 mg poly (dI-dC) and then for 15–20 min at room
temperature with approximately 50,000 cpm of labeled double-stranded
oligonucleotide end-labeled with [32P]cytidine 59-triphosphate. For com-
petition experiments, an excess of unlabeled doubled-stranded oligo-
nucleotides were added to the binding reactions. As a DR-3 type, we
used the Spp-1 VDRE 59-ACAAGGTTCACGAGGTTCACGTCT-39, and
the sequence 59-CCAGCCATGAATAAATGTTATAGGG-39 was used as
an unrelated oligonucleotide. For supershift experiments, 1 ml of specific
antibodies against VDR (aVDR) and RXR (aRXR) were added to the
binding reactions before the addition of the labeled fragment. Finally,
DNA-protein complexes were resolved on 6% polyacrylamide gels in
0.53 Tris-Borate-EDTA buffer. The gels were then dried and autora-
diographed at 270 C.
Results
Vitamin D inhibits the transcriptional response of the
RARb2 promoter to RA in GH4C1 cells
To analyze the effect of vitamin D on RA-mediated trans-
activation, the construct R-140 CAT containing the RARb2
promoter was transfected into GH4C1 cells. Fig. 1A shows
that treatment with 1 mm RA increased promoter activity by
approximately 5-fold in these cells. Incubation with concen-
trations of vitamin D, ranging between 0.1 and 100 nm, did
not affect basal activity of this plasmid, but it strongly re-
duced induction by RA. The inhibition of the transcriptional
response to RA was dose dependent. A half-maximal inhi-
bition was found at approximately 1 nm, and 10 nm vitamin
D caused a maximal reduction. The influence of RA and
vitamin D, in a construct that contains the DR-3 type VDRE
present in the osteopontin promoter fused to the tk promoter
(SPP-1-tk-CAT), was also analyzed in GH4C1 cells. Incuba-
tion with increasing concentrations of vitamin D transacti-
vated this promoter with a dose dependence similar to that
observed for transrepression of the RARb2 promoter. A half-
maximal effect was found at approximately 1 nm vitamin D,
and a maximal stimulation of 6-fold was obtained at 10 nm.
Interestingly, incubation with 1 mm RA increased basal SPP-
1-tk-CAT activity, although less strongly than vitamin D, and
potentiated the effect of vitamin D at the entire range of
concentrations used. Therefore, vitamin D can either inter-
fere with the response to RA on a DR-5 element, or it can have
an additive effect with the retinoid on a DR-3 element.
The contribution of the two RAREs of the RARb2 promoter
in the regulation by RA and vitamin D was analyzed in
GH4C1 cells transfected with the R-140 CAT plasmid, in
which both RAREs are present, or else with a plasmid con-
taining a shorter promoter fragment (R-90) in which the
distal RARE has been deleted. In addition, two R-140 CAT
constructs (M3 and M7) in which the 39 or 59 hemisites of the
proximal RARE have been mutated were also used. As
shown in Fig. 2B, deletion of the distal RARE did not de-
crease, but rather increased the response to RA in GH4C1
cells. In addition, vitamin D reduced the response of the
shorter construct to the retinoid, showing that the proximal
RARE is sufficient to mediate a potent transrepression by the
vitamin. Mutation of the proximal RARE strongly reduced
the response to RA, again demonstrating that this element is
the main one responsible for transactivation by RA, and
vitamin D blocked the residual stimulation of the mutant
promoter. These data suggest that the proximal bRARE me-
diates the repressive effect of vitamin D. This was also dem-
onstrated by the finding that vitamin D reduced similarly the
effect of RA on the natural RAREb2 promoter, and in an
heterologous construct (bRARE-tk-CAT), in which this
RARE was cloned in front of the tk promoter (data not
shown).
VDR/RXR heterodimers bind to the bRARE
To study whether the repressive action of VDR could
involve competition for DNA binding, in vitro-translated
VDR, RAR, and RXR were used for gel retardation assays
with the bRARE element (Fig. 3). In the absence of RXR,
neither RAR nor VDR bound to this element. However, in the
presence of the heterodimeric partner, not only RAR (lane 5),
but also VDR (lane 7), bound strongly to the bRARE. The
identity of the VDR/RXR heterodimer was demonstrated by
the finding that anti-VDR and anti-RXR antibodies (lanes 14
and 15, respectively) produced a supershift of the retarded
band. In addition, the formation of the VDR/RXR het-
erodimer was efficiently competed by an excess of the
bRARE and the strong SPP-1 VDRE element (DR3spp-1) but
not by an unrelated oligonucleotide (NR).
FIG. 1. Influence of vitamin D on tran-
scriptional responses to RA in GH4C1
cells. A, Cells were transfected with the
reporter plasmid R-140 CAT, which
contains the fragment 2124 to 114 of
the RARb2 promoter. After transfec-
tion, the cells were treated with increas-
ing concentrations of vitamin D alone
(empty circles) or in combination with 1
mM RA (full circles). CAT activity was
determined after 48 h. The data are ex-
pressed as a percentage of the values
obtained in the cells treated with RA in
the absence of vitamin D. B, GH4C1
cells were transfected with Spp-1-tk-
CAT, which contains the VDRE of the
osteopontin promoter cloned upstream
of the tk reporter. Treatments were the
same as in A, and CAT activity is ex-
pressed as fold induction over the val-
ues obtained in the untreated cells.
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Influence of overexpression of VDR and RAR on the
repressive effect of vitamin D
The levels of VDR and RAR should determine the amount
of each of these receptors bound to the response element, as
well as the net transcriptional response of the RAREb2 pro-
moter to vitamin D and RA. To analyze the effect of ratio
variations of these receptors, the cells were cotransfected
with the R-140 CAT plasmid and expression vectors encod-
ing VDR or RAR. As shown in Fig. 4A, cotransfection with
RAR significantly reverted the repression of the RA response
caused by vitamin D. Under these conditions, 1 nm vitamin
D did not reduce the response to RA, and 100 nm vitamin D
had an effect similar to that elicited by 1 nm vitamin D in
nontransfected cells. On the other hand, the dose-response
curve shifted to the left in cells transfected with VDR, and the
repressive effect of the vitamin was further enhanced. It
should be noted that this repression was strictly ligand-
dependent, because overexpression of VDR altered neither
basal promoter activity nor the response to RA.
The effect of varying the concentrations of VDR and RAR
in the presence of a constant amount of RXR on binding to
the bRARE is illustrated in Fig. 4B. Lanes 4–8 show that VDR
reduced RAR/RXR binding to DNA in a dose-dependent
manner. This reduction was accompanied by an increase in
VDR/RXR binding, although even at a VDR:RAR, 6:1 ratio
(lane 8), binding of VDR/RXR was weaker than that found
in the absence of RAR (lane 3). Similarly, increasing the
amount of RAR in the assay reduced VDR/RXR binding. A
complete inhibition was observed, even at a 1:0.75 ratio (com-
pare lanes 10 and 11), but again the intensity of the RAR/RXR
band in the presence of VDR (lane 14) was weaker than that
found in the absence of VDR (lane 9). This suggests a for-
mation of VDR/RAR heterodimers that would be unable to
bind to the bRARE. On the other hand, these results imply
that when the amounts of RXR are limiting, the binding of
both active RAR/RXR heterodimers and inactive VDR/RXR
heterodimers to the bRARE could be impaired.
Role of RXR on the response to VDR
In the experiment shown in Fig. 5A, it can be observed that
transfection with RXR enhanced the repressive effect of vi-
tamin D. This suggests that when RXR is not limiting the
amount of VDR/RXR bound to the bRARE could increase.
The influence of increasing concentrations of RXR on in vitro
RAR and VDR binding to the bRARE was analyzed in gel
retardation assays. As shown in Fig. 5B, when similar quan-
tities of RXR, VDR, and RAR were used (lanes 6 and 7),
RAR/RXR heterodimers were preferentially bound to the
bRARE. However, the presence of an excess of RXR allows
simultaneous binding of VDR/RXR and RAR/RXR het-
erodimers (lane 9). This binding was similar to that obtained
when VDR (lane 3) or RAR (lane 4) was independently in-
cubated in the presence of a high concentration of RXR. Lane
5 shows that binding of VDR/RAR to the bRARE was not
observed.
The above observations suggest that the VDR/RXR het-
erodimer is responsible for the repressive effect of vitamin D
on the response to RA. To analyze a possible role of the RXR
ligand on this repression, the cells were treated with vitamin
D in the presence and absence of 100 nm BMS649 (a RXR-
specific ligand). Because RXR (although with less affinity
than RAR) can also bind RA, in this experiment, the RARb2
promoter was stimulated with the RAR-specific retinoid
TTNPB. Incubation with BMS649 alone did not significantly
alter basal promoter activity, and this activity was not af-
fected by vitamin D (not illustrated). In contrast, as shown in
Fig. 5C, treatment with 100 nm TTNPB increased promoter
activity, and this response was repressed by vitamin D in a
FIG. 2. Regulation of RARb2 promoter
constructs by RA and vitamin D. A,
Schematic illustration of the constructs
used for transient transfection in
GH4C1 cells, showing the location of
the TATA box, the initiator (Inr), and
the proximal and distal RAREs (indi-
cated by arrows). R-140 contains both
RAREs, whereas R-90 contains only the
proximal element. In R-140 (M3) and
R-140 (M7), the 39 and 59 motifs of the
proximal RARE have been mutated. B,
CAT activity was determined in cells
transfected with the constructs indi-
cated above and incubated with 1 mM
RA in the presence and absence of 100
nM vitamin D. CAT activity is expressed
relative to the values obtained in the
corresponding group of untreated cells.
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dose-dependent manner. This repression was further en-
hanced when the cells were incubated with the combination
of vitamin D and the RXR-specific ligand (Fig. 5C). The
inhibitory effect of vitamin D on cells treated with 100 nm
BMS649 plus TTNPB was similar to that obtained in cells
treated with the same concentration of RA (illustrated by a
black triangle in the figure).
The LBD of VDR mediates a significant repressive effect
To investigate whether the repressive effect of vitamin D
in vivo depended on VDR/RXR binding to the RARb2 pro-
moter, we created a N-terminally truncated VDR (D1–111
VDR) that lacks regions A/B and C and that is, therefore,
unable to bind DNA. This truncation renders a 35-kDa re-
ceptor that does not bind to the bRARE but is able to reduce
binding of RAR/RXR because it contains the dimerization
domain (data not shown). The influence of over-expression
of this mutant receptor, as compared with the native VDR,
on the response of the R-140 construct to RA in GH4C1 cells
is shown in Fig. 6A. In agreement with results shown in Fig.
4A, the dominant inhibitory effect of vitamin D was further
enhanced in cells transfected with VDR. In addition, the
D1–111 VDR mimicked the effect of the wild-type receptor
and also increased the repressive effect of vitamin D, al-
though with a somewhat lower potency. This effect was
again strictly ligand-dependent because transfection with
native or truncated receptor affected neither basal promoter
activity nor induction by RA in the absence of vitamin D (not
illustrated).
To analyze whether the inhibitory influence of vitamin D
on the response to RA was specific for pituitary cells, the
effect of transfection with the native VDR and the D1–111
FIG. 3. VDR/RXR heterodimers bind to the bRARE. In vitro trans-
lated RAR, VDR, and/or RXR (1 ml) were used as indicated (lanes 3–7)
in gel retardation assays with an oligonucleotide conforming the prox-
imal RARE of the RAREb2 promoter (bRARE). Lane 1 shows the
mobility of the unretarded oligonucleotide and lane 2 shows the non-
specific band formed by the unprogrammed reticulocyte lysate (r.l.).
The position of this band is indicated by a circle, and the positions of
RAR/RXR and VDR/RXR heterodimers are shown by arrows at the
left. Increasing concentrations of the bRARE oligonucleotide, the
DR3-type VDRE of the osteopontin promoter (DR3spp-1), and a non-
related (NR) oligonucleotide (lanes 8–13) were used to compete the
retardation caused by VDR/RXR (lane 7). In lanes 14 and 15, the
VDR/RXR heterodimer was incubated with 1 ml of specific anti-VDR
(aVDR) and anti-RXR (a-RXR) antibodies, and the mobilities of the
corresponding supershifted bands are shown by arrows at the right.
FIG. 4. The ratio between RAR and VDR determines the activation
of the RARb2 promoter and in vitro binding to the bRARE. A, GH4C1
cells were cotransfected with the R-140 CAT construct and an empty
noncoding vector pSG5–0 (squares) or vectors expressing RAR (tri-
angles) or VDR (circles). After transfection, the cells were treated for
48 h with the concentrations of vitamin D indicated, either alone
(empty symbols) or in combination with 1 mM RA (full symbols). CAT
activity obtained in cells treated with RA in the absence of vitamin D
was considered in each case as a 100%. B, Gel retardation assays with
the bRARE oligonucleotide and 1 ml of RXR in the presence of in-
creasing concentrations (between 0 and 6 ml) of VDR and RAR. The
amount of in vitro translated receptors or reticulocyte lysate used is
indicated at the top. The circle shows the mobility of the nonspecific
retarded band formed by the unprogrammed lysate.
2902 VITAMIN D REPRESSES RARb2 PROMOTER ACTIVATION Endo • 1999
Vol 140 • No 6
 by on May 17, 2010 endo.endojournals.orgDownloaded from 
mutant was also examined in COS-7 cells. The expression of
endogenous VDR and the transfected receptors are shown in
Fig. 6C. As analyzed by Western blot, VDR was undetectable
in untransfected COS-7 cells, and both the native and trun-
cated VDR were expressed at similar levels. Because these
cells also express low levels of RARs, the RARb2 promoter
was always cotransfected with an expression vector encod-
ing RAR. The left panel in Fig. 6B shows that, under these
conditions, RA activated the promoter, and incubation with
100 nm vitamin D did not affect this response in the absence
of exogenous VDR. The middle panel shows that, after ex-
pression of VDR, vitamin D caused a significant inhibition of
the promoter response to RA, similar to that observed in
GH4C1 cells that express high levels of endogenous VDR. As
shown in the right panel, again the receptor lacking the A/B
domain and the DBD was able to mediate a significant li-
gand-dependent transrepression.
Deletion of the AF-2 domain of VDR impairs
transrepression by vitamin D
To analyze whether the AF-2 domain, which is required
for ligand-dependent stimulation by VDR, is also involved in
ligand-dependent transrepression, we constructed an AF-2-
defective mutant receptor (DAF2 VDR). This receptor, which
lacks only the last C-terminal 12 residues, heterodimerizes
and binds normally to the bRARE (data not shown) and is
expressed at the same levels as the native VDR after trans-
fection in cells (Fig. 7B). However, as illustrated in Fig. 7A,
the AF-2 mutant showed a reduced ability to mediate a
ligand-dependent inhibition of the RA response. Whereas
overexpression of VDR again significantly potentiated re-
pression by vitamin D in GH4C1 cells, overexpression of
DAF2 VDR had little effect on this inhibitory response. Sim-
ilar results were obtained in COS-7 cells transfected with
FIG. 5. Influence of RXR on RARb2 promoter activation and binding of VDR and RAR to the bRARE. A, GH4C1 cells were cotransfected with
the RARb2 promoter in the presence (circles) and absence (squares) of an expression vector for RXR. The data are expressed as a percentage
of the values obtained in the cells treated with RA alone in each condition. The cells were then treated for 48 h with vitamin D alone (empty
symbols) or in combination with 1 mM RA (full symbols). CAT activity obtained in cells treated with RA in the absence of vitamin D was considered
as a 100%. B, The bRARE oligonucleotide was used for retardation assays with 1 ml RAR or 1 ml VDR in the presence of increasing amounts
of RXR (between 0 and 6 ml), as indicated. The mobility of two nonspecific bands produced by 8 ml reticulocyte lysate is shown by circles at the
left. C, GH4C1 cells were transfected with R-140 CAT. After transfection, the cells were treated for 48 h with 100 nM TTNPB, a RAR-specific
ligand, in the presence of the concentrations of vitamin D indicated, alone (square symbols) or in combination with 100 nM BMS649, a
RXR-specific ligand (circles). CAT activity is expressed as the percentage of the values obtained in cells treated with TTNPB or TTNPB1BMS649
in the absence of vitamin D. The black triangle represents the data obtained in cells treated in parallel with 100 nM RA plus 100 nM vitamin
D, as a percentage of the value obtained with RA alone. The data represent the mean of two independent transfections, with less than 10%
variation.
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expression vectors for VDR and DAF2 VDR. Whereas incu-
bation with 100 nm vitamin D almost totally inhibited RA-
dependent activation of the R-140 CAT construct in cells
transfected with native VDR, the inhibition mediated by the
AF-2-defective receptor was significantly impaired (Fig. 7C).
E1A partially reverses the inhibitory response of vitamin D
The finding that the AF-2 domain seems to be required for
the dominant negative activity of VDR suggests that titration
of coactivators or common associated proteins that bind to
this region may be involved in the inhibition of the RA
response. If this hypothesis were true, overexpression of
these factors should revert transrepression by vitamin D. A
cellular counterpart of adenoviral E1A seems to play a co-
activator role in the regulation of the RARb2 promoter. E1A
has been shown to cooperate with TBP in synergistically
increasing the response of this promoter to RA. This is not
observed in GH4C1 cells, in which transfection with E1A
and/or TBP had little effect on the response to RA (Fig. 8).
However, expression of E1A was able to significantly reduce
the inhibitory effect of vitamin D on the RARb2 promoter,
both in the presence and absence of TBP, suggesting that
titration of an E1A-like activity could contribute to the re-
pression caused by vitamin D. In contrast with the effect of
E1A on the RARb2 promoter, expression of this protein did
not alter the induction of the Spp1-tk-CAT construct by vi-
tamin D, showing that E1A does not exert a nonspecific effect
on vitamin D responses (data not shown). On the other hand,
overexpression of the coactivators SRC-1 or CBP in GH4C1
cells altered neither the response of the RARb2 promoter to
RA nor the repressive effect of vitamin D. Similar results
were obtained after transfection with TFIIB, which interacts
with VDR and has been described to modulate transcrip-
tional responses to vitamin D (data not shown).
FIG. 6. The LBD of VDR mediates transrepression by vitamin D. A, GH4C1 cells were cotransfected with the RARb2 promoter construct and
expression vectors encoding wild-type VDR or a truncated receptor (D1–111 VDR), which lacks the A/B domain and the DBD. CAT activity was
determined in cells treated with 1 mM RA in the presence of the indicated concentrations of vitamin D. B, Cos-7 cells were transfected with a
noncoding vector or with expression vectors for VDR and D1–111 VDR. Expression of these proteins was assessed by Western blot, 48 h after
transfection. The size of the receptors (in kDa) is shown at the left. C, R-140 CAT was cotransfected into COS-7, together with 0.2 mg of a RAR
expression vector and the vectors expressing native VDR or D1–111 VDR. CAT activity was determined, after 48 h, in cells treated with 1 mM
RA in the presence and absence of 100 nM vitamin D.
FIG. 7. The AF-2 domain of VDR participates in transrepression of the RARb2 promoter by vitamin D. A, GH4C1 cells were cotransfected with
R-140 CAT and a noncoding vector, an expression vector for wild-type VDR, or a vector expressing a receptor in which the last 12 C-terminal
residues have been deleted (DAF-2 VDR). CAT activity was determined after 48 h of incubation with 1 mM RA in the presence of the indicated
concentrations of vitamin D. B, Levels of VDR and DAF-2 VDR obtained in COS-7 cells transfected with vectors encoding these receptors. C,
COS-7 cells were transfected with R-140 CAT and the VDR and DAF-2 VDR vectors. The cells also received 0.2 mg RAR. CAT activity was
determined in cells treated with 1 mM RA and/or 100 nM vitamin D, and the data are expressed as the percentage of the values obtained in the
corresponding untreated cells.
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Discussion
We show that vitamin D exerts an important repressive
effect on RA-dependent transactivation of the RARb2 pro-
moter in pituitary GH4C1 cells that express functional re-
ceptors for both ligands (10). In these cells, nanomolar con-
centrations of vitamin D, which stimulate transcription of
promoters containing a VDRE, effectively inhibited activa-
tion by RA. We found this inhibitory response to be specific,
because vitamin D did not decrease basal RARb2 promoter
activity. Repression seems to be mediated by the RARE lo-
cated between 237 to 253 on the promoter and can be
transferred to a heterologous promoter. In EC cells, deletion
of upstream sequences (from 2124 to 259) which contain an
imperfect RARE, diminish RA-dependent transactivation in
vitro (29) and in vivo (15). However in GH4C1 cells, deletion
of these sequences does not impair, but rather increases,
transactivation. These results indicate that the distal RARE
does not enhance the RA response in these cells, although
this element could contribute to transrepression by vitamin
D. A putative phorbol ester-responsive element at position
284 to 278 and a cAMP-responsive element at position 299
to 292 adjacent to the distal RARE have been described to be
involved in RA-dependent RARb2 promoter activation in EC
cells (30, 31). These elements could be involved in the ob-
served cell type-specific reduction of the RA response. In any
case, vitamin D also reduced RA-dependent transactivation
of a construct that does not contain these sequences, showing
that the proximal bRARE is sufficient to confer the transre-
pressive effect. In the context of the longer promoter frag-
ment, a mutation in the RXR 59 half-site of the bRARE (re-
porter M7) essentially abolished the response to RA, whereas
mutation of the 39 half-site, which binds RAR (reporter M3),
significantly decreased (but did not totally block) this re-
sponse. A stronger effect of the mutation in the RXR-specific
half-site has also been observed in in vitro transcription as-
says (29). Our results demonstrate that this residual response
is also abolished by vitamin D in GH4C1 cells.
Our findings also show that VDR/RXR heterodimers bind
to the bRARE with high affinity, although this binding is
transcriptionally unproductive. The discrepancy between
binding and activity is likely caused by the conformation
acquired by the heterodimers in a DR-5 element, which may
affect its interaction with other factors required for transcrip-
tional activation. Other examples of receptor binding to
HREs in a transcriptional inactive form have been previously
described. In particular, we have observed unproductive
binding of VDR/RXR to a palindromic HRE, which also
binds RAR/RXR heterodimers (10). An attractive mecha-
nism has been proposed to explain the lack of activation by
RA of RAR/RXR heterodimers bound to a DR1 element.
Ligand-transactivation by RAR on a DR5 element seems to
require the dissociation of corepressors, as well as the re-
cruitment of coactivators (32). In DR1 elements, because of an
altered heterodimer polarity, corepressors remain associ-
ated, even in the presence of RA, resulting in constitutive
repression (33). However, a mechanism of transrepression by
vitamin D involving corepressor molecules is very unlikely,
because VDR does not bind the corepressors SMRT or NCoR
in solution (34, 35). Furthermore, we have shown that SMRT
does not associate with RXR/VDR bound to the bRARE
(A. M. Jimenez-Lara and A. Aranda, submitted for publica-
tion). The possibility that unidentified corepressors different
from SMRT could be involved in transrepression cannot be
dismissed; but the fact that, in the absence of ligand, VDR
does not cause a repressive effect in the transfection assays
makes this possibility highly unlikely. On the other hand, the
promoter context in which a HRE is placed can be the de-
termining factor for receptor selectivity. Thus, DR3 and DR4
elements, which normally mediate vitamin D and thyroid
hormone responses, are converted to exclusive RAREs when
placed in the RARb2 promoter (15).
A competitive DNA binding mechanism between active
RAR/RXR heterodimers and inactive VDR/RXR het-
erodimers could contribute to transrepression of the RA-
dependent transactivation of the RARb2 promoter by vita-
min D. In fact, in in vitro assays, VDR displaced RAR/RXR
binding to the bRARE. This competition occurred when RXR
was limiting, because the presence of an excess of RXR al-
lowed binding of both heterodimers. Transfection experi-
ments suggested that RXR also plays a role in the promoter
inhibition mediated by VDR and that the VDR/RXR het-
erodimer can be the in vivo transrepressing species. Further-
more, a RXR-specific ligand potentiated the negative inhib-
itory effect of vitamin D. It has been proposed that RXR
ligands can inhibit transactivation by VDR/RXR het-
erodimers by promoting the formation of RXR homodimers
(36, 37). The possibility that RXR homodimers could cause
repression of the RA response can be dismissed, because
incubation of GH4C1 cells with an RXR-specific ligand alone
did not affect transactivation. Therefore, our results indicate
that the ligands of both heterodimeric partners cooperate to
transrepress the RARb2 promoter.
Although DNA binding could be important for full po-
tency-dominant inhibitory activity of VDR, other mecha-
nism/s must contribute to this inhibition. This is based on the
finding that a truncated receptor lacking the DBD also dis-
plays repressor activity in GH4C1 and COS-7 cells, although
the repression is somewhat weaker than that mediated by the
native receptor. The truncated receptor could act by seques-
tering RXR and, consequently, by causing a decrease in the
amount of this receptor available for the formation of active
RAR/RXR heterodimers. Titration of RXR has been de-
FIG. 8. Expression of E1A partially reverses the inhibitory effect of
vitamin D on the RARb2 promoter. GH4C1 cells were transfected
with R-140 CAT and expression vectors for E1A (5 mg), the TBP (15
mg), or both. CAT activity was determined in cells treated with 1 mM
RA and/or 100 nM vitamin D for 48 h.
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scribed to mediate repression of RA-dependent transactiva-
tion of the RARb2 promoter by the thyroid hormone receptor
(38). If competition for RXR were to be responsible for
transrepression by vitamin D in GH4C1 cells, it would be
expected that this inhibitory effect would disappear in the
presence of excess amounts of RXR. However, vitamin D also
blocked the response to RA after transfection of RXR.
On the other hand, the N-terminally truncated VDR also
contains the AF-2 domain responsible for binding of coac-
tivators and ligand-dependent transactivation. Our studies
reveal that the C-terminal region of VDR, a putative amphi-
pathic helix that contains the AF-2 domain (39, 40), is in-
volved in transrepression, because a receptor lacking the last
12 aminoacids mediates little inhibition by vitamin D. A
reduced ligand-binding affinity of the AF-2-defective VDR
could explain the reduced transrepressive effect of this re-
ceptor. However, similar deletion mutants have been shown
to bind ligand with high affinity (5, 40), and this mutant
shows a clearly impaired ability to mediate repression in
COS-7 cells treated with a saturating concentration of vita-
min D. On the other hand, this VDR mutant binds to DNA
and heterodimerizes normally with RXR. It has been recently
demonstrated that deletion or mutation of the AF-2 domain
abrogates ligand-dependent interaction of VDR with the co-
activators SRC-1, SUG1, and RIP-140 (39, 40). E1A has been
shown to play an important role in RA-dependent transac-
tivation of the RARb2 promoter (15, 20). E1A also contacts
the AF-2 domain of RAR and may be considered to be a
RARb2 promoter-specific coactivator (22). Our results show
that expression of E1A in GH4C1 cells significantly reduces
transrepression by vitamin D without altering basal pro-
moter activity. These findings suggest that VDR could titrate
endogenous factors that can be substituted by the viral pro-
tein. The existence of a E1A-like activity in EC cells has been
postulated (20), although this factor has not been purified or
cloned yet. This E1A-like activity should exist in pituitary
cells, because overexpression of E1A does not cause further
stimulation of RA-dependent transactivation of the RARb2
promoter, as it occurs in Cos cells that do not express this
activity. E1A has a complex function in cells and can interact
with a variety of effectors. Therefore, the nature of the factors
that may be squelched by VDR in GH4C1 cells is unknown
at the present. Another coactivator, which plays an impor-
tant role in transcriptional activation mediated by different
signaling pathways (including those modulated by nuclear
receptors) is CBP/p300. This cointegrator contacts both the
the AF-2 domain of the nuclear receptors and components of
the basal transcriptional machinery, such as TBP or TFIIB (27,
41). Furthermore, CBP also binds E1A (42) and might act as
a bridging factor between E1A-LA, RAR, and TBP. That led
to the possibility that titration of this factor, which seems to
be present in limiting amounts in several cell types (43),
could be responsible for the inhibitory effect of vitamin D on
the RA response. However, in GH4C1 cells, overexpression
of CBP did not increase the response of the RARb2 promoter
to RA and did not revert repression by vitamin D. Thus,
either CBP is not a good coactivator for this particular pro-
moter or, most likely, this coactivator is expressed in suffi-
cient amounts in these cells to elicit maximal responses. The
same is true for other coactivators (such as SRC-1) or for some
components of the basal transcriptional machinery (such as
TBP or TFIIB), which regulate transcriptional responses to
vitamin D (44, 45), because we did not observe modulation
of the promoter response to RA or vitamin D after overex-
pression of these factors in GH4C1 cells. Therefore, other still
unidentified coactivators that bind to both RAR and VDR
could be involved in transrepression by vitamin D.
We had previously reported that RA and thyroid hor-
mones induce an increase in GH transcripts in pituitary cells
and that vitamin D interferes with this activation (10). This
shows that transrepression also occurs with the endogenous
genes. These findings, as well as the results obtained in the
present work, demonstrate an important repressive role of
VDR on some transcriptional responses to other nuclear re-
ceptors in this cell type. Although the role of vitamin D on
pituitary ontogeny and function remains to be established,
the interaction of vitamin D and retinoid signaling must be
complex, because we have observed that (depending on the
response element involved) these ligands can also cooperate
to stimulate transcription. This seems to be the case with the
pituitary-specific transcription factor GHF-1/Pit-1, which
plays a key role in the expression of pituitary genes, as well
as in pituitary development. The study of the GHF-1/Pit-1
gene promoter revealed the existence of a DR4 element that
responds positively both to RA and vitamin D (46). A balance
between stimulatory and inhibitory actions of vitamin D
must create a complex and sensitive transcriptional network
in the pituitary. It is clear that further studies on the phys-
iological impact of the observed repression for the function
or development of pituitary cells merits further investiga-
tion. The importance of transrepression by vitamin D is prob-
ably not restricted to these cells. We have observed here that
RA-dependent activation of the RARb2 promoter is also re-
pressed by vitamin D in Cos-7 cells after expression of VDR.
Therefore, it is expected that vitamin D could modulate RA
responses in different cell types that coexpress VDRs and
RARs.
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